CoChat

Prevalence, clinical and economic burden of mucormycosis-related hospitalizations in the United States: a retrospective study

Open access

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Mucormycosis is a rare but devastating fungal infection primarily affecting immunocompromised patients such as those with hematological malignancy, bone marrow and solid organ transplantation, and patients with diabetes, and, even more rarely, immunocompetent patients. The objective of this study was to assess the prevalence and burden, both clinical and economic, of mucormycosis among hospitalized patients in the U.S. METHODS: Comparative Database, with more than 560 participating hospitals covering 104 million patients (January 2005-June 2014). All hospitalizations in the database were evaluated for the presence of mucormycosis using either an ICD-9 code of 117.7 or a positive laboratory result for Mucorales. Hospitalizations were further required to have prescriptions of amphotericin B or posaconazole to be considered as mucormycosis-related hospitalizations. The prevalence of mucormycosis-related hospitalizations among all hospital discharges was estimated. Mortality rate at discharge, length of hospital stay, and readmission rates at 1 and 3 months were evaluated among mucormycosis-related hospitalizations. Cost per hospital stay and average per diem cost (inflated to 2014 USD) were reported. RESULTS: The prevalence of mucormycosis-related hospitalizations was estimated as 0.12 per 10,000 discharges during January 2005-June 2014. It increased to 0.16 per 10,000 discharges if the definition of mucormycosis was relaxed to not require the use of amphotericin B or posaconazole. The median length of stay was 17 days, with 23% dead at discharge; readmission rates were high, with 30 and 37% of patients readmitted within one and three months of discharge, respectively. The average cost per hospital stay was $112,419, and the average per diem cost was $4,096. CONCLUSIONS: The study provides a recent estimate of the prevalence and burden of mucormycosis among hospitalized patients. The high clinical and economic burden associated with mucormycosis highlights the importance of establishing active surveillance and optimizing prophylactic and active treatment in susceptible patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12879-016-2023-z

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Prevalence of mucormycosis-related hospitalizations. Note: [1] Mucormycosis encounters with drug restriction were identified using ICD-9 codes or laboratory results and required at least one use of amphotericin B or posaconazole
Fig. 1 Prevalence of mucormycosis-related hospitalizations. Note: [1] Mucormycosis encounters with drug restriction were identified using ICD-9 codes or laboratory results and required at least one use of amphotericin B or posaconazoleCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 27 references

Cited by

See all 132

Metadata

Authors
Kontoyiannis, D. P., Yang, H., Song, J., Kelkar, S. S., Yang, X., Azie, N., Harrington, R., Fan, A., Lee, E., & Spalding, J. R.
Affiliations
  • The University of Texas MD Anderson Cancer Center (US)
  • Analysis Group (United States) (US)
  • Astellas Pharma (United States) (US)
Corresponding author
Kontoyiannis, Dimitrios P.
Venue
BMC Infectious Diseases
Published
2016-12
Volume
16
Issue
1
Pages
730-730
ISSN
1471-2334 (ISSN-L)
OpenAlex
W2557575310
Cited by
132
References
27
Citations by year
2026: 5 · 2025: 14 · 2024: 13 · 2023: 15 · 2022: 18 · 2021: 21 · 2020: 8 · 2019: 17 · 2018: 13 · 2017: 8
FWCI
11.69
Type
journal article
Language
en
Open access
Locations
  • BMC Infectious Diseases (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
Astellas Pharma Global Development (NA)
Topics
  • Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
  • Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
  • Health Sciences › Medicine › Infectious Diseases › Infectious Diseases and Mycology
Keywords
mucormycosis, Mucorales, prevalence, hospitalization burden, economic burden, mortality, length of hospital stay, hospital readmission, health care costs, amphotericin B, posaconazole, immunocompromised patients, hospitalized patients
MeSH terms
Adolescent, Adult, Aged, Antifungal Agents, Child, Female, Hospitalization, Humans, Length of Stay, Male, Middle Aged, Mucormycosis, Retrospective Studies, United States, Prevalence, Databases, Factual, Cost of Illness, Hospital Costs, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Prevalence, clinical and economic burden of mucormycosis-related hospitalizations in the United States: a retrospective study. https://app.cochat.ai/papers/10.1186/s12879-016-2023-z
The paper
Kontoyiannis, D. P., Yang, H., Song, J., Kelkar, S. S., Yang, X., Azie, N., Harrington, R., Fan, A., Lee, E., & Spalding, J. R. (2016). Prevalence, clinical and economic burden of mucormycosis-related hospitalizations in the United States: a retrospective study. BMC Infectious Diseases. https://doi.org/10.1186/s12879-016-2023-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.